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Introduction
Hospital readmission rates for COPD patients are
high, with two-week readmission rates of 22%
being recorded in one study of patients with acute
exacerbation of chronic obstructive pulmonary
disease (AECOPD).1 In a separate study, patients
admitted with PaCO2 > 50 mm Hg had a read-
mission rate of 40% at six months.2 There are no
agreed clinical evidence factors that determine
readmission. A few studies have reported that
readmission is associated with an individual’s
inability to cope with the disease, and that anxi-
ety and socioeconomic status are important vari-
ables. 3-5 Others argue that readmission relates to
severity of lung function abnormality, changes in
atmospheric pollution, and impaired quality of life
(QoL). 6-9
In the United Kingdom 81 500 people aged
above 65 years died of COPD between 1990 and
1992. 10 During severe AECOPD, inpatient mor-
tality is estimated at between 11% and 14%, 2,11
and this figure is even higher in those patients
admitted to the intensive care unit.12 Inpatient
mortality is associated with elevated PaCO2, low
bodymass index and low maximal inspiratory
mouth pressure.11,13-14 Conversely, epidemiologi-
cal studies consistently report that low baseline
forced expiratory volume in one second (FEV1) is
the most powerful mortality predictor,15-18 and
that mortality is associated with age.15,16
A review of predictors of mortality and hospi-
tal admissions is timely, as the morbidity of COPD
is projected to increase in the next two decades
and COPD-related health-care expenditure is
exponentially rising in both Europe and the
United States.19-21
This review explores the risk factors that may
be associated with AECOPD, duration of admis-
sion, episodes of readmission and mortality. We
have also explored the management of AECOPD
and the outcome of rehabilitation programmes for
this patient group.
For the review, potentially relevant studies were
extracted by searching English-language articles
(Medline 1976–2000 and Cinahl 1982–2000).
This was complemented by hand-searching of arti-
cles reviewed in bibliographies of papers identi-
fied as above. The following search terms were
used: chronic obstructive pulmonary disease
(COPD), hospitalization and mortality. Studies
that did not include the term COPD plus either
‘mortality’ or ‘hospitalization’ were excluded. 
Acute exacerbation and hospital admission
AECOPD is common in elderly patients and costly
to treat. An individual may commonly experience
one to four mild or severe exacerbations per
annum. 22 Severe exacerbations are a frequent
cause of hospital admission. Symptoms may
include breathlessness, purulent sputum and
increased sputum volume. Bacterial respiratory
infection is a major cause of admission and com-
monly reported pathogens 23, 24 in sputum culture
may include Haemophilus influenzae, Strepto-
coccus pneumoniae, Staphylococcus aureus, Pseu-
domonas aerugionsa and Moraxella catarrhalis. 
Recent meta-analysis of randomized controlled
trials in the use of antibiotics in this situation
identified a small but clinically significant benefit
of antibiotic use. 25 The British Thoracic Society
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guidelines for management of COPD 26 state that
patients presenting with two or more of the
above-mentioned symptoms of AECOPD should
be treated with antibiotics. This guideline chal-
lenged the blanket approach which had been used
in clinical practice, and suggested a more rigorous
investigation that might help physicians to pre-
scribe appropriate antibiotics in order to reduce
the emergence of drug-resistant pathogens.
In one UK study, over 10% of all hospital
admissions of elderly patients were due to rela-
tively minor COPD exacerbations in individuals
who were disabled by respiratory impairment, and
for every 1000 elderly patients on a general prac-
titioner list there were 700 GP consultations for
AECOPD per year. 27
Risk factors associated with hospital admission
Chronic mucus hypersecretion (CMH) may be
associated with admission episodes in elderly
COPD patients. Vestbo et al. ,28 in a longitudinal
study, demonstrated that, in patients with CMH,
FEV1 declined at a mean rate of 22.8ml per
annum and, after adjusting for FEV1, relative risk
of subsequent hospitalization was approximately
2.5 times that of non-CMH patients, in whom
FEV1 decline was only 12.6ml p.a. In contrast, a
previous longitudinal study reported little effect of
CMH on COPD prognosis.29
Collet et al.30 has suggested the potential ben-
efits of an immunostimulating agent in improving
the immune mechanism and possibly the severity
of respiratory events that may lead to hospital
admission. Conversely, Niewoehner et al.31 inves-
tigated the effects of systemic glucocortocoids in
AECOPD patients. They showed that glucocorti-
coids had modest benefit in reducing length of stay
and that the benefit was partially maintained for
six months. 
Recent findings by Bhowmik et al.32 showed
that sputum inflammatory markers in the stable
state (raised baseline sputum cytokine levels) are
good predictors of future episodes of exacerba-
tion. In addition, Kessler et al. 33 identified pul-
monary hypertension as an independent predictor
of hospital readmission.
Repeated exacerbations are associated with loss
of self-esteem and decrease in physical activities,
in turn leading to impaired quality of life.7,8
Geraci et al. 34 examined the prevalence of in-hos-
pital complications of three chronic conditions:
congestive cardiac failure, diabetes and COPD.
There was no statistically significant difference in
the prevalence rate of complications (15.7%,
14.8% and 13.1%) between the three conditions.
The most frequent cause of inpatient complica-
tion for COPD patients was theophylline toxicity.
Other factors that related to inpatient complica-
tions were patient characteristics such as age and
presence of co-morbid diseases. For each condi-
tion, complications lead to an increased length of
stay.
Recently, Dewan and associates,35  in an ele-
gant study, showed that, after AECOPD, treat-
ment failure defined as ‘return visit for persistent
respiratory symptoms that required a change of
antibiotic in under four weeks’, was associated
with low FEV
1
(< 35% predicted), use of home
oxygen therapy and frequency of exacerbations.
In a separate study, recovery from AECOPD was
prolonged in those identified with increased dys-
pnoea and upper respiratory tract infection at the
onset of exacerbation. 36 Others have shown that
longer duration of hospitalization relates to high
PaCO2 levels and to antibiotic treatment begun
prior to admission.37
Sin and Tu 38 investigated short-term versus
longer-term hospital stay in elderly patients with
AECOPD. Early discharge (less than four days of
hospital stay) was associated with a high relapse
rate (39% readmission and 45% mortality rate
within two weeks) and also increased health-care
usage compared to those who stayed longer than
four days in hospital.
Cigarette smoking 
Elderly COPD subjects who remain active smok-
ers have more rapid deterioration in lung func-
tion than ex-smokers.39,40 Furthermore, continued
smoking is associated with impaired QoL and
with high health-care resource usage in COPD
patients. 41 In one study, it was reported that
smoking tended to have a greater impact (more
FEV1 decline) in women
39 than in men. Active
smoking has been related to episodes of exacer-
bations and increased drug prescription.42 The
British Thoracic Society guidelines emphasize 43
the benefits of smoking cessation in reducing
health-care usage and averting the spiral of lung
function decline. Health-care professionals should
play an active role in encouraging smokers to
stop, and provide them with appropriate support
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and help. A recent editorial review44 highlighted
the benefits of smoking cessation for elderly
COPD patients. Smoking cessation programmes
should include the provision of advice and edu-
cation on successful quitting, nicotine replacement
therapy, the regular monitoring of the patient’s
condition and medium-term and long-term 
support. 
Atmospheric pollution and seasonal variation
It is well-recognized9,45–47 that ‘black smoke’,
smog and exposure to airborne particles and to
ozone are causes of emergency hospital admission
and GP visits for elderly patients with COPD. Sea-
sonal variations and climatic changes may affect
patients’ perception of their well-being. Vilkman
et al.48 have shown excess hospital admission and
relapses of exacerbations in the winter, compared
to summer, months. However, perhaps surpris-
ingly, no difference was observed in the seasonal
variation in the use of emergency medical services
for elderly asthmatic and COPD patients.49
Current initiatives to reduce hospitalization 
In a controlled study, Gravil et al.50 examined the
benefits of a ‘hospital-to-home’ service for
AECOPD patients. AECOPD patients, after for-
mal hospital assessment, were released to be cared
for by nurses at home. There was a reduction in
treatment costs, number of exacerbations and
hospital admissions, and over 80% of subjects
were satisfied with the service and happy to be
treated at home. Some, though not all, previous
studies51–54 of similar initiatives have demon-
strated not only reduced hospitalization but also
improved quality of life and sense of well-being,
self-esteem and social interaction. A hospital-
based intervention study by Tougaard et al.55
claimed that teaching COPD patients about their
illness reduces the health-care costs by increasing
patients’ knowledge of disease and hence their
ability to manage themselves. 
Clini et al.56 examined the benefits of an inten-
sive home-care programme in three groups of
COPD patients with chronic hypercapnia who
were randomly allocated to home mechanical ven-
tilation and long-term oxygen therapy (LTOT) or
LTOT only, or control (normal standard treat-
ment). The findings suggested a reduction in sub-
sequent hospital admission in the two ‘treated’
groups compared to the control group.
Table 1 summarizes the factors recognized to
be associated with hospital admission in COPD.
A multimodal approach to tackle the problem is
clearly needed.
Predictors of mortality in COPD
In England and Wales in the past decade, the num-
ber of deaths from COPD has been increasing.57
Several studies have identified factors associated
with mortality in COPD patients (Table 2). Dif-
ferences in methodology, socioeconomic status of
subjects and availability of health-care resources
make it difficult to extrapolate from these stud-
ies. However, they may act as a platform to iden-
tify potential at-risk patients and plan appropriate
treatment strategies.
Connors et al.2 examined survival rates in a
six-month period after severe AECOPD, and
found death was associated with severity of exac-
erbation, low bodymass index and co-morbid
factors, such as presence of corpulmonale and
congestive cardiac failure. In longitudinal studies
in elderly COPD populations, mortality seems to
be associated with smoking status and physical
disability.58–60 Other studies have shown death
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Table 1. Risk factors associated with hospital
admission in COPD
Low FEV1
Chronic mucus hyper-secretion
Atmospheric air pollution 
Flu outbreaks or epidemics 
Clinical anxiety
Physical disability
Severity of respiratory impairment 
Age
Co-morbid illness 
Impaired quality of life
Table 2. Risk factors associated with mortality in
COPD
Low FEV1
Age
Low body-mass index
Pulmonary hypertension
Low PaO2
High PaCO2
Smoking status
Co-morbid illness
rate from COPD to be associated with defects in
carbon monoxide transfer,61 clinical depression
and difficulty in coping with the disease,62 and
with cognitive impairment.63 There also appears
to be an unusual inverse association with total
serum cholesterol.64
Long-term oxygen therapy and survival 
Long-term domiciliary oxygen therapy (LTOT)
improves survival in COPD patients with chronic
hypoxaemia.65,66 However, in the Nocturnal Oxy-
gen Therapy Trial,65 mean patient age was 65
years, and the Medical Research Council66 stud-
ied only COPD patients aged < 70 years. In both
studies, subjects were predominantly men. The
evidence-base for the benefits of LTOT in elderly
COPD patients is not known, and research in this
area would be valuable. Furthermore, others have
been unable to demonstrate the benefits of LTOT
in prolonging survival in moderately hypoxaemic
COPD patients.67 Storm68 investigated the causes
of mortality in COPD patients receiving LTOT.
Increased mortality was associated with use of
oral corticosteroids, poor physical performance
and female gender. Others identified the signifi-
cance of pulmonary artery pressure greater than
30 mm Hg as a prognostic factor for survival in
patients receiving LTOT.69 In this study neither
FEV1 nor degree of hypoxaemia or hypercapnia
were mortality predictors. Earlier studies70,71 have
also reported that pulmonary hypertension is a
strong predictor of mortality. In the advanced
stage of COPD, the presence of hypercapnoea car-
ries a poor prognosis. Zielinski et al.72 investi-
gated the cause of death in elderly LTOT patients
and found (not surprisingly) that the majority
died from acute or chronic respiratory failure. The
survival rate in COPD patients (Table 3) with
chronic respiratory failure is generally poor (five-
year survival estimated at 27%)73 This emphasizes
the importance of smoking cessation, the only
intervention known to limit progression to respi-
ratory failure in COPD.
Socioeconomic status and mortality
Prescot and Vestbo74 observed that the mortality
impact of socioeconomic status on individuals
with COPD is enormous and second only to cig-
arette smoking. The death rate in those with low
socioeconomic status was twice that of those in
higher social classes. In old age, the impact of
COPD is very considerable, as the combination of
disease and relative poverty leads to social isola-
tion and an inability to participate in social activ-
ities. This in turn may contribute to the high
prevalence of depressive symptoms reported in
this patient group.75,76
In a community survey not exclusive to COPD
patients, House et al.77 showed that passive soli-
tary activities (watching television, listening to
radio and reading) seem to relate to higher mor-
tality compared to physically active pastimes in
old age. Sedentary lifestyle, loneliness and passive
solitary activities are a common scenario for many
elderly COPD patients.
Co-morbid factors associated with mortality in
COPD
Incalzi et al.78 have confirmed that the diseases
commonly associated with COPD include hyper-
tension, diabetes mellitus and ischaemic heart dis-
ease. Death in this patient group was predicted by
ECG signs of right ventricular hypertrophy and
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Table 3. Survival analysis in COPD patients
Studies Number Mean Gender Mean FEV1 Duration of Percentage
age M/F in litres follow up mortality
Gray-Donald et al. 199614 348 63 237/ 111 0.71 5 years 47%
Traver et al. 197616 200 59 178/22 – 15 years 88%
Vestbo et al. 199817 487 67 267/220 – 5 years 45%
Yohannes et al. 200059 137 73 69/68 0.89 1 year 16%
Ashutosh et al. 199762 16 62 16 0.75 4 years 44%
Oswald-Mamsor et al. 199569 84 63 75 / 9 0.83 5 years 48%
Keller et al. 198570 87 63 71/16 0.94 3 years 45%
Costello et al. 199773 85 68 61/24 0.73 5 years 73%
myocardial infarction or ischaemia, and by
chronic renal failure. In addition Lynn et al.79 has
shown that nearly 40% of patients with advanced
COPD have three or more co-morbidities. A case-
controlled study by Cappel and Nadler80 investi-
gated acute upper gastrointestinal bleeding with
and without COPD, and confirmed a higher death
rate in COPD sufferers. This bi-directional effect
of co-morbid disease on mortality confirms the
clinical impression of practitioners.
Comparison of death from asthma and COPD 
Cydulka and associates,22 in an eight-year obser-
vational study, compared hospital usage, length of
stay and inpatient mortality in elderly COPD suf-
ferers and asthmatics. Elderly COPD patients
were twice as likely to die during hospitalization,
had longer lengths of stay and higher health care
usage. Similar findings were observed in a twenty-
year longitudinal study.81,82 One possible explana-
tion for these differences might be the
pathological process of the disease, that is,
asthma has reversible characteristics, while COPD
is irreversible and, in the presence of continued
smoking, is progressive in nature. Keistinen et
al.81 suggest that thorough investigations of
‘COPD’ patients admitted at the first hospitaliza-
tion or before, should take place, to plan appro-
priate treatment strategies and in particular to
identify reversibility.
Do pulmonary rehabilitation programmes reduce
morbidity and mortality?
Recent randomized controlled trials (mean age
62–68 years) have demonstrated the benefits of
pulmonary rehabilitation (PR) programmes in
improving exercise capacity and quality of life in
COPD patients. The benefits of PR may be sus-
tainable for up to 12 months.83–85 There was no
difference in survival or hospital admission
between the rehabilitated group compared with
the controls,84,85 but a slight reduction in the
length of hospital stay in favour of the rehabili-
tated group. One would assume that if rehabili-
tation improves general well-being, then this
improvement should be translated to a reduction
in morbidity, if not mortality. The absence of such
a relationship is puzzling, and further study is
worthy of consideration. 
Conclusion
AECOPD is a major cause of hospital admission
and high health-care usage in elderly patients.
Factors associated with hospital admission and
mortality in elderly COPD patients are complex
and may be physiological, social or environmen-
tal. To reduce the health-care expenditure, mor-
bidity and mortality of COPD patients,
self-management, education and pulmonary reha-
bilitation programmes (particularly including
smoking-cessation strategies) are essential. Fur-
thermore, early identification of risk factors may
help health-care providers, patients and carers in
planning appropriate treatment. Finally, discharge
planning should include attempts to prevent
future episodes of exacerbation and admission by
planning follow-up visits, lifestyle management
and activity levels, identifying an early-warning
system of the signs of exacerbation and providing
the support required at home .
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